Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

(2015) Toshiaki Watanabe et al.   International Journal of Clinical Oncology

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)

(2014) M. Yoshida et al.   ANNALS OF ONCOLOGY

A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome

(2014) Shoichi Hazama et al.   Journal of Translational Medicine

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

(2012) Koji Kono et al.   Journal of Translational Medicine

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer

(2010) KIYOTAKA OKUNO et al.   Experimental and Therapeutic Medicine

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY